Anti-Rheumatics Market Size, Share & Trends Analysis Report By Drug Class (Disease Modifying Anti-Rheumatic Drugs, Nonsteroidal Anti-inflammatory Drugs, Corticosteroids, Uric Acid Drugs, Others), By Type (Prescription-Based Drugs, Over-the-Counter Drugs) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Anti-Rheumatics Market Insights

The global anti-rheumatics market size was valued at USD 68.03 billion in 2025 and is projected to grow from USD 69.87 billion in 2026 to USD 86.46 billion by 2034, registering a CAGR of 2.7% during the forecast period from 2026 to 2034. North America dominated the anti-rheumatics market with a market share of 38.4% in 2025.

Anti-rheumatics is a category of drugs that are used to treat a variety of symptoms that are associated with rheumatoid arthritis. These drugs are effective in the treatment of a variety of conditions affecting the connective tissue, including systemic sclerosis (SSc), systematic lupus erythematosus (SLE), and Sjogren syndrome (SS). These drugs also effectively treat inflammatory myositis and intestinal illnesses, among the conditions that can be addressed. For administration into the body, they can be taken orally, injected subcutaneously (SC), or delivered intravenously (IV). They help reduce inflammation, which in turn helps prevent joint damage, reduce pain and swelling, and decrease the progression of arthritis. Rheumatologists, gastroenterologists, and dermatologists worldwide are increasingly considering anti-rheumatic medications as a potential course of treatment for their patients because of this.

Rheumatoid arthritis is an inflammatory arthritis that causes severe swelling and stiffness in the joints. It is the most common form of autoimmune arthritis. In addition to this, it has the potential to irritate the skin, the eyes, the lungs, the heart, and the blood vessels. As a consequence of this, the rising prevalence of this particular medical condition is one of the primary factors that is driving demand for anti-rheumatic drugs all over the world.

Drug Class Insights

The market is bifurcated into disease-modifying anti-rheumatic drugs, nonsteroidal anti-inflammatory drugs, corticosteroids, uric acid drugs, and others. The disease-modifying anti-rheumatic drugs segment dominates the global market and is projected to exhibit a CAGR of 2.9% over the forecast period. Rheumatoid arthritis progression can be slowed down with the help of disease-modifying anti-rheumatic drugs (DMARDs). For instance, DMARDs can delay the progression of rheumatoid arthritis, resulting in fewer symptoms and less joint damage. Furthermore, there are two types of DMARDs on the market: conventional and biologics. Methotrexate and hydroxychloroquine are two further examples of conventional DMARDs. Enbrel and Humira are two biological medications that can be purchased to treat rheumatoid arthritis.

Additionally, biologics target specific immune proteins known as cytokines, while conventional DMARDs inhibit the immune system generally. The rise in awareness of the use of anti-rheumatics for the treatment of rheumatoid arthritis and the rise in the prevalence of the disease are the two main reasons contributing to the market's expansion. The industry is also being driven by the global increase in healthcare spending and the growth of the elderly population. The market is growing due to the extra advantages DMARDs provide, such as slowing the progression of arthritis.

Request Customizationto receive a tailored report.

Type Insights

The market is segmented into prescription-based drugs and over-the-counter drugs. The prescription-based drugs segment is the most significant contributor to the market and is estimated to exhibit a CAGR of 2.8% over the forecast period. To supply a substance requiring a prescription, you must legally have a valid medical prescription. These are useful because they ensure that patients undergoing treatment for rheumatoid arthritis receive the appropriate dose of the drug without causing a significantly increased number of unwanted effects. This is why they are helpful. The most frequently recommended medications to patients are uric acid drugs and disease-modifying anti-rheumatic drugs, or DMARDs for short. Other anti-rheumatic treatments include Humira (adalimumab), Enbrel (etanercept), and Cimzia (certolizumab pegol), and each of these drugs is only available with a prescription from a medical professional.

Speak to an Analystto discuss market opportunities.

Regional Insights

North America is the most significant global anti-rheumatics market shareholder and is estimated to exhibit a CAGR of 3.0% over the forecast period. Due to the rising frequency of rheumatoid arthritis in this region, North America held the greatest proportion of the worldwide market. For example, the Arthritis Society estimates that 300,000 Canadians have rheumatoid arthritis. As a result, there is an increase in demand for anti-rheumatics in the area due to the rising prevalence. Another important element driving the market for anti-rheumatics is the rise in the elderly population. Anti-rheumatic drug demand is, therefore, increased because older adults are more likely to develop rheumatoid arthritis.

Additionally, simple access to anti-rheumatic drugs and increased healthcare spending are anticipated to fuel market expansion in this area. Due to the rise in rheumatoid arthritis prevalence, North America held the greatest market share. This trend is predicted to continue during the projected period. A major driver of the anti-rheumatics market's expansion is also the rise in the elderly population. Significant important companies like Bristol-Myers Squibb Company, Merck & Co., Inc., Amgen Inc., AbbVie Inc., Pfizer, Inc., and Eli Lilly and Company are also driving the market in the region.

Unlock Regional Insightsto access country-level data, & regional trends.

Europe Anti-Rheumatics Market Trends

Europe is anticipated to exhibit a CAGR of 2.4% over the forecast period. Europe held the second-largest proportion of the global market because of factors like the presence of major players and broad knowledge of the effectiveness of these drugs in treating rheumatoid arthritis. In addition, a big senior population and a large patient base for rheumatoid arthritis are key factors that support the market's expansion. As a result, it is projected that the vast patient pool will raise demand for anti-rheumatic drugs, which are necessary to treat rheumatoid arthritis. Increased healthcare spending is one of the key elements driving market expansion in the area. The rise in rheumatoid arthritis prevalence, which increases demand for anti-rheumatics, is one of the causes driving the expansion of these medications in the area.

In Asia-Pacific, the market has plenty of attractive potential, which is also expected to develop at the fastest rate over the projected period. The countries in this region are densely populated, with China and India ranking first and second, respectively. Therefore, the Asia-Pacific anti-rheumatics market is anticipated to increase due to the region's ability to provide a sizable customer base. Rising healthcare costs and increased knowledge of anti-rheumatics use are also driving the market's expansion.

In addition, the rise in rheumatoid arthritis incidence in the area is another factor driving the market's expansion. The leading companies in the market may have opportunities due to a sizable prospective customer base and the rise in awareness of using anti-rheumatics for treating rheumatoid arthritis in Asia-Pacific. Additionally, a rise in healthcare spending in the area drives market expansion. Another significant factor driving the expansion of the market in Asia-Pacific is the region's rising prevalence of rheumatoid arthritis.

In LAMEA, the anti-rheumatics market is in its infancy due to low purchasing power, shortage of advanced healthcare facilities, inadequate health expenditure, and inadequate health coverage. The Brazilian healthcare system consists of a large public component, a small paid health insurance component, and a small private component in which consumers pay for medical services out of pocket. This hinders the development of anti-rheumatics in this region.

However, governments of various LAMEA nations have increased spending in the healthcare sector to entice key actors to expand their operations in the region. In addition, an increase in the prevalence of rheumatoid arthritis in the region leads to a rise in demand for faster healthcare services, which drives the market's expansion. LAMEA is an emerging market because healthcare expenditures are anticipated to increase during the forecast period, generating lucrative growth opportunities for market participants. A high prevalence of rheumatoid arthritis is another significant factor contributing to expanding the market in this region.

List of Key and Emerging Players in Anti-Rheumatics Market